Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.52 |
| ▸ | PDE4A | P27815 | 2/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.52 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.48 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.48 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.48 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.48 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.48 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.48 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.48 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.48 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.48 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.48 |
| ▸ | CACNG1 | Q06432 | 1/20 | 0.48 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1927899 | 0.93 | USP30 (0.52) | KDM1AGPR119PDE4BPDE4DPDE4A | |
| SCHEMBL30657430 | 0.89 | KDM1A (0.56) | KDM1AGPR119PDE4BPDE4DPDE4A | |
| SCHEMBL26639643 | 0.89 | KDM1A (0.56) | KDM1AGPR119PDE4BPDE4DPDE4A | |
| SCHEMBL29079727 | 0.88 | GPR119 (0.55) | KDM1AGPR119PDE4BPDE4DPDE4A | |
| SCHEMBL29079766 | 0.88 | KDM1A (0.55) | KDM1AGPR119PDE4BPDE4DPDE4A | |
| SCHEMBL3954269 | 0.87 | USP30 (0.47) | KDM1AGPR119PDE4BCACNB4CACNA1A | |
| SCHEMBL19839235 | 0.86 | PDE4B (0.64) | KDM1AGPR119PDE4BPDE4DPDE4A | |
| SCHEMBL21765007 | 0.86 | KDM1A (0.57) | KDM1AGPR119PDE4BPDE4DPDE4A | |
| SCHEMBL74564 | 0.86 | KDM1A (0.57) | KDM1AGPR119PDE4BPDE4DPDE4A | |
| SCHEMBL2773558 | 0.85 | GPR119 (0.58) | KDM1AGPR119PDE4BPDE4DPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115606-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2025-04-10 | — | — | US | disclosed |
| US-12221442-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-20240246962-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2024-07-25 | — | — | US | disclosed |
| EP-4334302-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11926626-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| CN-116406360-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-07-07 | — | — | CN | disclosed |
| US-20230107793-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-04-06 | — | — | US | disclosed |
| US-20230071840-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-03-09 | — | — | US | disclosed |
| WO-2022235698-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| EP-2982666-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-20090099200-A1 | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK FROSST CANADA LTD. (CA) | 2009-04-16 | — | — | US | disclosed |
| EP-2027121-A1 | CYCLIC AMINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2009-02-25 | — | — | EP | disclosed |
| EP-1902051-A1 | AZACYCLOHEXANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007134457-A1 | CYCLIC AMINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2007-11-29 | — | — | WO | disclosed |
| US-7186715-B2 | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-03-06 | — | — | US | disclosed |
| WO-2006130986-A1 | AZACYCLOHEXANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2006-12-14 | — | — | WO | disclosed |
| EP-1370558-B1 | PIPERAZINE- AND PIPERIDINE-DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | LILLY CO ELI (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20040082590-A1 | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-04-29 | — | — | US | disclosed |
| EP-1370558-A1 | PIPERAZINE- AND PIPERIDINE-DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002059117-A1 | PIPERAZINE- AND PIPERIDINE-DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246962-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | KDM1A 1496/4885GPR119 9/4885PDE4B 143/4885 |
| US-12221442-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, GCGR | KDM1A 1496/4885GPR119 9/4885PDE4B 143/4885 |
| US-20250115606-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | KDM1A 1496/4885GPR119 9/4885PDE4B 143/4885 |
| US-20230071840-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | KDM1A 1496/4885GPR119 9/4885PDE4B 143/4885 |
| US-20040082590-A1 | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | MC1R, MC4R, MC5R | KDM1A 1633/4885GPR119 10/4885PDE4B 734/4885 |
| US-20090099200-A1 | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | SCD, SCD5, SREBF1 | KDM1A 707/4885GPR119 74/4885PDE4B 2543/4885 |
| US-11926626-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, GCGR | KDM1A 1496/4885GPR119 9/4885PDE4B 143/4885 |
| US-20230107793-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | KDM1A 1496/4885GPR119 9/4885PDE4B 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.